Searched for
LUPIN REVENUE GROWTH
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Stocks in news: HDFC Bank, ICICI Bank, RIL, Trent, Jio FinancialIndian markets are set for a dynamic start today. Investors will closely watch the Q4 results from banking giants HDFC Bank and ICICI Bank....
- Time to buy? Sunny Agrawal finds best picks across banking, pharma, capital markets & infrastructureIndian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...
- Lupin shares jump 2% as Q2 PAT soars 73% YoY to Rs 1,485 croreLupin shares rose on Friday after the pharma major reported a robust 73% YoY surge in Q2 FY26 PAT to Rs 1,485 crore, driven by strong sales...
- Drug companies set for improved revenue growth in June quarter amid US market challengesIndian pharma and healthcare companies anticipate improved revenue and profit in the June 2025 quarter, fueled by domestic market growth. H...
- CDMO sector to be key beneficiary of China+1 strategy in pharma: Vishal ManchandaSystematix Group's Vishal Manchanda anticipates Q4 results for pharma companies to align with previous quarters, with high single-digit dom...
- Lupin shares drop 3% after Q3 resultsShares of Lupin Ltd dropped 2.8% despite a significant Q3 profit increase of 38.8% year-on-year. The company's revenue surged 102.7%, reach...
- US show a plus for Cipla, Lupin confident of recoveryThe domestic business grew 6 per cent, showing the impact of a high base effect.
- Stock pick of the week: Why analysts are bullish on LupinIn addition to growth in sales in respective markets, favourable currency movement has also helped Lupin to achieve high growth.
- Rising local sales, strong drug pipeline may nurse Lupin back to healthAfter a stellar show in earlier years, where it grew an average 20 per cent annually , it has been difficult for Lupin to sustain growth.
- US Generic launches are key to Lupin growthLupin's revenue grew 5% yearon-year to Rs 3,144.9 crore during the December 2014 quarter, much lower than the analysts' expectation of 12-1...
- Looking to acquire companies and launch new products in India: LupinHomegrown drug major Lupin is looking to acquire companies and launch new products in the domestic market as it aims to scale up its Indian...
- Lupin Pharma's India business a cause for concernLupin Pharma’s underperformance in the domestic market may rein in investors’ bullish stance on the share — a hitherto darling of the India...
- Local manufacturing can boost margins for LupinFor a fairly consistent performer in terms of top line growth in the pharma industry, drug maker Lupin’s show in the quarter to December wa...
- Lupin scouts for buys in Latin AmericaThe company expects to launch 10 new products in Japan this year, considered the most difficult of three developed pharmaceutical markets -...
Load More
